BTK and lymphoid leukemia: In recent years, BTK inhibitors, for instance Ibrutinib and Acalabrutinib (ACP-196), have achieved success in the treatment of lymphocytic leukemia, whereas their clinical activity against solid tumors is limited (Overman et al., 2020), (Tempero et al., 2021).